Navigation Links
Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment

WILMINGTON, Del., March 20, 2013 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the leading biobutanol technology company, announced today it would appeal the Court's claim construction and decisions on certain motions before the Court in Butamax's litigation against Gevo.

Paul Beckwith , Butamax Chief Executive Officer, stated, "Butamax has decided to appeal this case immediately.  Butamax strongly disagrees with the Court's claim construction.  We do not believe it is consistent with either the patent, rules for patent claim construction or statements made by the Federal Circuit.  We have therefore decided to appeal immediately to resolve this matter before going to trial.  We are confident the Federal Circuit will determine this matter in our favor."

The Court made no overall determination on literal infringement and denied Gevo's motions of invalidity on all but two of 37 patent claims being asserted by Butamax against Gevo.  However, despite previous statements from the Federal Circuit, the Court chose a very narrow claim construction for the KARI enzyme element of the claims.  This narrow interpretation, in Butamax's view, is in error as a matter of law and therefore Butamax is taking this claim construction immediately back to the Federal Circuit for appeal.

Beckwith continues, "This is still an early stage in what is likely to be a long and complicated litigation, involving many patents that will take several years for the courts to resolve.   Butamax is currently enforcing six other patents against Gevo and will vigorously continue to do so while this case is appealed."

Butamax remains strongly committed to near term commercialization of its biobutanol technology.  Butamax will continue its strategy of bringing advanced biofuels to the consumer and providing a real solution to the blendwall.

About Butamax 

Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:  
Mark Buse  202-679-5576


SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
3. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
4. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
5. USPTO Grants Butamax a Further KARI Enzyme Patent
6. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
7. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
10. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
11. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
Post Your Comments:
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
Breaking Biology News(10 mins):